Overview

Obesity is a widespread public problem with complex etiology. The greater prevalence of obesity also increases the risk of diabetes, cardiovascular disease, etc., among others. The development of efficient and specific therapeutic strategies is necessary for the treatment of obesity and related complications. As a novel therapeutic approach, Cell Therapy has great potential to treat obesity and its complications. A variety of specific anti-obesity cell therapies have been developed and are being investigated for their effectiveness in treating obesity, including stem cell therapy, CAR-T cell therapy, etc. CAR-T cell therapy, which works by specifically redirecting T cells to specific cells, has good potential for treating obesity. Protheragen offers a high-quality CAR-T cell therapy development service based on years of research experience and high technical competence. We customize the development process to meet the needs of CAR-T cell therapy development.

Unlocking New Therapeutic Insights for Obesity Through Cutting-edge CAR-T Cell Therapy Development Services

At Protheragen, we are committed to accelerating the development and research of CAR-T cell therapies. With our experienced team and state-of-the-art facilities, we offer a one-stop service from therapy development to preclinical studies. We fully understand the pathogenesis of obesity and potential therapeutic strategies, and meet our clients' CAR-T cell therapy development needs with innovative solutions. Specific CAR-T cell anti-obesity therapy strategies include the following:

CAR-T Cell Therapy Development

We conduct in-depth studies on the molecular mechanisms of obesity to screen for suitable targets, such as urokinase plasminogen activator receptor (uPAR), and use them as the basis for CAR-T cell therapy development. After identifying suitable targets, T cells are isolated and purified from animal models. This is followed by efficient modification through gene editing techniques, including insertion and knockout of characteristic genes in the T cells. After transplanting the CAR-T cells back into the animals, the efficacy of the therapy is validated through comprehensive preclinical validation and promotes the development and research of transformative anti-obesity cell therapies.

CAR candidate molecule discovery: CAR is mainly composed of extracellular structural domains, transmembrane structural domains, and intracellular structural domains. The generation and optimization of single-chain variable fragments (scFv) of monoclonal antibodies in the extracellular domain lays the most basic foundation for effective and specific CAR-T therapies. We employ multiple strategies to generate scFv with the most favorable affinity.

CAR-T cell construction: We integrate CAR sequences into T cells. This process is carried out using precision gene editing technology, which ensures the safer insertion of CAR sequences at specific sites. At the same time, high-throughput screening methods ensure that experiments are conducted accurately and efficiently.

Functional validation: The constructed CAR T-cells are ready for functional validation, such as CAR expression assay, in vitro drug efficacy assessment, in vivo safety and efficacy assessment, pharmacokinetic information investigation, etc. We provide customized solutions according to clients' experimental needs.

Preclinical Studies of Anti-Obesity Therapies

Obesity models: We have constructed a variety of in vitro Cell Models to evaluate the in vitro efficacy of CAR-T cells. In addition to this, we have a variety of high-quality obesity models (e.g., Mice, Rats, etc.). Our research team develops CAR-T cells and evaluates their anti-obesity effects in these obese animal models to support preclinical studies of CAR-T cell therapies. These animal models are also being used to evaluate the safety of CAR-T cells, including normal targeting.

Evaluation of the effectiveness of therapy: The efficacy of CAR T-cell therapy is evaluated by in vitro experiments. At the same time, after injecting the cells, we detect physiological and pathological changes in the animal models, including gene expression profiling, glucose tolerance, insulin tolerance assay, histological analysis, CAR T-cell content change detection, etc. We evaluate the effectiveness of CAR-T cell therapy through the changes in the physiological conditions of the animal model. In addition to this, we are evaluating the safety of this therapy to provide data to support further optimization of the therapy.

Workflow

Applications

• Metabolic syndrome research: Obesity and metabolic syndrome are interrelated and share multiple pathophysiological mechanisms. CAR-T cell therapy also holds promise for the treatment of metabolic syndrome.
• Combination therapy research: CAR-T cell therapy is used in combination with other weight loss interventions or anti-obesity treatments to enhance their effectiveness.
• Obesity-associated cancers research: CAR-T cell anti-obesity therapies have potential applications in the study of therapeutic approaches for obesity-associated cancers.

Advantages

• Our scientists and research team have extensive expertise in CAR-T cell therapy development and have conducted numerous studies on its application to obesity treatment.
• We communicate closely with our clients at every stage, from initial consultation to implementation of experimental protocols, and keep them updated on the progress of their CAR-T cell therapy development projects.
• We understand the uniqueness of each project and accelerate our clients' anti-obesity therapies through efficient solutions.

Other Cutting-edge Services for Obesity Research

In addition to the development of anti-obesity therapies, we have constructed a comprehensive obesity causation analysis and testing service system, which aims to explore the multifactorial root causes of obesity. We also utilize cutting-edge diagnostic tests and cutting-edge algorithms to support obesity prediction and evaluation of obesity interventions. Our team shows excellence in the analysis of obesity biomarkers, pathology characterization, and microbiome studies. Editing of obesity-related genes is also our forte. In addition, we provide a high level of weight loss and weight management services, with real-time testing to ensure that the weight loss process is scientific and efficient.

Publication Data

Frequently Asked Questions

What are the advantages of CAR-T cell therapy?

T cells are genetically engineered to carry CARs that can target specific loci and act. With our understanding of the molecular mechanisms of obesity, we screen for suitable targets and genetically modify the T cells using advanced techniques such as lentiviral transduction and plasmid transfection. Our service process starts with a consultation to understand your specific needs. We then isolate T cells from animal models and genetically modify them. Afterward, we perform a thorough validation to analyze the potential of this therapy in the treatment of obesity.

Do we offer any other anti-obesity cell therapy development services besides CAR-T cells?

In addition to CAR-T cells, stem cells hold great promise for the treatment of obesity. We also offer stem cell therapy development services. By genetically modifying various stem cells (induced pluripotent stem cells, mesenchymal stem cells) and transplanting them into animal models, we detect physiological and pathological changes in the animals.

Protheragen specializes in obesity-related research and provides an innovative CAR-T cell therapy service. We keep abreast of international research advances and work tirelessly to provide truly cutting-edge solutions for our clients. Welcome to contact us for more information or to discuss the details of CAR-T cell therapy development and experience unrivaled expertise and support.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Stem Cell Therapy Development